How Much Does AndroGel Cost in Delaware in 2026?

Delaware Retail Cash Price for AndroGel

The average cash price for a 30-day supply of brand-name AndroGel 1.62% at Delaware retail pharmacies sits at approximately $510 in 2026. This figure aligns with AbbVie's current manufacturer list price and has remained relatively flat since 2024. Patients without insurance or those whose plans exclude brand-name testosterone gel face this full retail burden.

A generic version of testosterone gel 1% (the older formulation) is available and typically costs between $200 and $350 per month at Delaware pharmacies, depending on the dispensing pharmacy and quantity. The 1.62% concentration that defines the current AndroGel product does not yet have a direct generic equivalent. Price variation across Delaware's three counties is minimal. Pharmacies in Wilmington, Dover, and the beach communities quote similar figures because wholesale acquisition costs remain uniform statewide. GoodRx and similar discount aggregators occasionally list prices $30 to $60 below retail, but availability fluctuates by location and fill date [1].

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies enrolling 790 men aged 65 and older with serum testosterone below 275 ng/dL, confirmed that testosterone gel improved sexual function, physical activity, and mood over 12 months [2]. That evidence base supports the ongoing clinical use of topical testosterone for confirmed hypogonadism, making cost access a practical concern for the roughly 4 to 5 million American men estimated to have low testosterone by the American Urological Association [3].

Delaware Medicaid Coverage for Testosterone Gel

Delaware Medicaid covers AndroGel for the treatment of male hypogonadism, but a prior authorization (PA) is required before the state program will reimburse. The PA process typically demands documentation of two morning serum total testosterone levels below 300 ng/dL, drawn on separate days, along with a clinical diagnosis consistent with the Endocrine Society's 2018 guideline [4].

Processing times for PA requests in Delaware run between 24 and 72 hours for standard requests. Urgent PAs can receive same-day decisions. If the initial PA is denied, patients have the right to appeal through the Delaware Division of Medicaid and Medical Assistance (DMMA). Common reasons for denial include incomplete lab documentation, a single testosterone level rather than the required two, or a total testosterone value above the state's coverage threshold.

Delaware Medicaid may also cover the generic testosterone gel 1% formulation, often with a lower PA threshold or a preferred-drug-list (PDL) advantage. Prescribers should check the current Delaware Medicaid PDL quarterly update, as formulary positioning shifts. "Prior authorization exists to confirm that testosterone therapy is clinically indicated rather than elective," noted the Endocrine Society's 2018 clinical practice guideline on testosterone therapy in men with hypogonadism [4]. That guideline recommends treatment only when symptoms and biochemical confirmation both support the diagnosis.

Insurance Coverage Beyond Medicaid

Most major commercial insurers operating in Delaware, including Highmark Blue Cross Blue Shield Delaware, Aetna, and Cigna, include some form of testosterone gel on their formularies. Coverage specifics vary by plan tier.

Highmark BCBS Delaware, the state's largest commercial carrier, generally places brand-name AndroGel on Tier 3 (non-preferred brand), while generic testosterone gel 1% sits on Tier 2 (preferred brand). Tier 3 copays typically range from $50 to $100 per fill depending on the specific plan. Tier 2 copays fall between $25 and $60. Step therapy requirements may apply. Some plans require that patients try generic testosterone gel 1% or injectable testosterone cypionate before approving brand-name AndroGel 1.62%.

Employer-sponsored plans through larger Delaware employers (DuPont/Corteva, ChristianaCare, and state government) frequently carry their own formulary rules. State employee plans through the Delaware Group Health Insurance Plan (GHIP) have historically covered testosterone replacement with standard PA requirements similar to Medicaid.

The FDA-approved labeling for AndroGel specifies its indication for replacement therapy in adult males with conditions associated with a deficiency or absence of endogenous testosterone, including primary hypogonadism and hypogonadotropic hypogonadism [5]. Insurers rely on this labeled indication as the baseline for coverage decisions.

Compounded Testosterone Gel in Delaware

Compounded testosterone gel from licensed 503A pharmacies is legal and available in Delaware, typically costing around $120 per month. That price point represents a 76% savings compared to brand-name AndroGel.

Delaware follows federal law under the Drug Quality and Security Act (DQSA) of 2013, which permits state-licensed 503A compounding pharmacies to prepare patient-specific testosterone gel formulations when a valid prescription exists [6]. Several compounding pharmacies operate within Delaware, and patients can also receive compounded testosterone gel shipped from out-of-state 503A pharmacies licensed to dispense into Delaware.

There are trade-offs. Compounded products do not undergo FDA-approved bioequivalence testing. Absorption rates, gel consistency, and testosterone delivery may vary between compounding pharmacies. The Endocrine Society has not taken a formal position against compounded testosterone but has noted that "compounded testosterone products are not subject to the same regulatory oversight as FDA-approved products" [4]. Patients considering this route should verify that their compounding pharmacy holds current state licensure and, ideally, PCAB (Pharmacy Compounding Accreditation Board) accreditation.

A compounded 1% testosterone gel is the most common formulation. Some 503A pharmacies also compound testosterone cream in higher concentrations (e.g., 10% or 20%) applied in smaller volumes, which some patients prefer. These cream formulations are not bioequivalent to AndroGel and should be dosed and monitored independently.

The AbbVie Savings Card Program

AbbVie, the manufacturer of AndroGel, offers a copay savings card that can reduce out-of-pocket costs to $0 per month for eligible commercially insured patients. The card covers up to a set maximum annual benefit, historically between $1,800 and $2,400 per year depending on the program cycle.

Eligibility rules are straightforward but firm. Patients must have commercial insurance that covers AndroGel (even partially). Medicare Part D beneficiaries, Medicaid enrollees, TRICARE members, and patients using any other federal or state healthcare program are excluded from the savings card by federal anti-kickback statute requirements. Uninsured patients do not qualify for the copay card but may qualify for AbbVie's separate patient assistance program (myAbbVie Assist), which provides AndroGel at no cost to patients below 400% of the federal poverty level.

To activate the card, patients enroll through the AbbVie AndroGel website or receive a card through their prescriber's office. The card is presented at the pharmacy alongside the insurance card at each fill. Processing happens at the point of sale. No reimbursement claims or mail-in forms are needed.

One limitation: if a patient's insurer does not cover AndroGel at all (hard exclusion, not just PA-required), the savings card typically will not apply because there is no insurance claim to adjudicate against. In those cases, the patient faces the full cash price.

Telehealth Access to AndroGel in Delaware

Delaware permits testosterone prescribing via telehealth. The state updated its telehealth regulations during the COVID-19 public health emergency and subsequently made many of those flexibilities permanent through Delaware Senate Bill 208 (2021), which established parity for telehealth services.

Testosterone gel is a Schedule III controlled substance under the DEA's classification. Federal law (the Ryan Haight Act) historically required an in-person evaluation before prescribing controlled substances via telemedicine, but the DEA's 2025 final telemedicine rule now permits an initial telemedicine consultation for Schedule III through V substances if the prescriber conducts a real-time audio-visual evaluation and follows state-specific requirements [7].

Delaware-licensed prescribers (MDs, DOs, NPs, and PAs with prescriptive authority) can initiate testosterone gel therapy through a telehealth visit provided they order and review appropriate laboratory work. Standard practice requires at minimum two morning total testosterone levels, a complete metabolic panel, lipid panel, CBC with hematocrit, and PSA for men over 40 before initiating therapy [4].

Several national telehealth TRT platforms serve Delaware patients. Pricing for telehealth TRT consultations ranges from $99 to $199 per visit at direct-to-consumer platforms, with some offering subscription models that bundle the consultation, lab work, and compounded testosterone gel for $150 to $250 per month total.

How to Minimize Your Cost in Delaware

The cheapest pathway depends on your insurance status. Here is how the math breaks down.

For commercially insured patients whose plan covers AndroGel: activate the AbbVie savings card. Combined with insurance, monthly out-of-pocket may drop to $0 to $30. If step therapy forces a trial of generic testosterone gel 1% first, that alternative still costs substantially less than brand at $25 to $60 in copays.

For uninsured patients: compounded testosterone gel from a Delaware-licensed 503A pharmacy at ~$120 per month is the most cost-effective option. Injectable testosterone cypionate (200 mg/mL, 10 mL vial) remains even cheaper at roughly $30 to $80 per month but requires intramuscular injection rather than daily topical application.

For Medicaid patients: work with your prescriber to complete the PA documentation thoroughly on the first submission. Include both morning testosterone levels, the ICD-10 code for hypogonadism (E29.1 for primary, E23.0 for secondary), and a brief clinical note explaining symptoms. Clean submissions reduce denial rates significantly.

"We recommend testosterone therapy for men with symptomatic testosterone deficiency to induce and maintain secondary sex characteristics and to improve sexual function, sense of well-being, muscle mass and strength, and bone mineral density," states the Endocrine Society's 2018 guideline [4]. That recommendation underscores that cost-reduction strategies should aim to maintain access to therapy, not interrupt it.

For patients already on therapy who face a coverage gap or plan change, a 90-day supply through mail-order pharmacy (where available on the plan) typically offers a 10 to 15% per-unit savings over 30-day retail fills.

Monitoring Costs to Factor In

The drug cost is not the entire expense. Ongoing testosterone therapy requires regular blood work. The Endocrine Society recommends checking total testosterone, hematocrit, and PSA at 3 to 6 months after initiation, then annually [4]. A basic testosterone and CBC panel costs $50 to $150 out of pocket at Delaware labs (Quest Diagnostics and Labcorp both operate draw stations statewide). Most insurance plans cover these labs as medically necessary when ordered by a prescriber for diagnosed hypogonadism.

Hematocrit monitoring is particularly important. The TTrials found that testosterone treatment increased hematocrit levels, with 2.1% of testosterone-treated men exceeding 54% hematocrit compared to 0.5% in the placebo group [2]. Polycythemia (hematocrit above 54%) requires dose reduction or temporary cessation, adding potential cost through additional visits and repeat labs.

The FDA's boxed warning on testosterone products, updated in 2015, notes an increased risk of major adverse cardiovascular events (MACE) and requires that prescribers confirm hypogonadism with lab testing before initiation [5]. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found that transdermal testosterone was noninferior to placebo for MACE incidence (hazard ratio 0.96 to 95% CI 0.78 to 1.17), providing some reassurance regarding cardiovascular safety in men aged 45 to 80 with pre-existing cardiovascular disease or elevated risk [8].

Baseline and follow-up DXA scans for bone density assessment may be clinically indicated for men with severe or longstanding hypogonadism. A DXA scan in Delaware ranges from $125 to $350 out of pocket, though most insurers cover it when medically justified.

Delaware-Specific Pharmacy Options

Delaware's small geography means most patients are within 20 minutes of multiple retail and compounding pharmacies. Wilmington (New Castle County) has the highest pharmacy density. Kent and Sussex counties have fewer options but still maintain CVS, Walgreens, and Rite Aid locations that stock AndroGel or can order it within 24 hours.

For compounded testosterone gel, several 503A pharmacies operate in the greater Wilmington area. Patients in southern Delaware may find it more practical to use a compounding pharmacy that ships, as 503A pharmacies are permitted to ship patient-specific compounds within and across state lines when properly licensed.

Costco pharmacies in Delaware (Christiana and Wilmington locations) often quote lower cash prices on generic medications than traditional retail chains, though pricing for brand-name AndroGel tends to remain near the $510 manufacturer price regardless of pharmacy. The Costco pharmacy does not require a Costco membership for prescription purchases under federal law.